Lead Development and Optimization Shared Resource ? Project Summary The Lead Development and Optimization Shared Resource (LDOSR) is a University of Kansas Cancer Center (KUCC) shared resource composed of three functions: 1) High Throughput Screening (HTS); 2) Medicinal Chemistry (MC); and 3) the Biotechnology, Innovation and Optimization Center (BIOC). Collectively, these three functions allow the LDOSR to accelerate projects from early method development around cancer pathways or targets, through high throughput screening, compound hit prioritization, secondary in vitro confirmatory assays, medicinal chemistry optimization, in vitro pharmacology testing, in vivo pharmacokinetics and drug delivery formulations for in vivo preclinical proof-of-concept testing. The LDOSR has modified its composition and activities over the past four years in order to provide the best possible support to KUCC members. The Preclinical Proof of Concept (PPOC) service was eliminated from the LDOSR at the end of 2012 because many KUCC members had similar functionality within their own laboratories. Furthermore, it was realized that the LDOSR would be enhanced by a dedicated medicinal chemistry expert. Therefore, Frank Schoenen joined the LDOSR to provide medicinal chemistry optimization services. In 2014, the LDOSR formed a project management service known as the Target Acceleration Group (TAG).
TAG aims to accelerate projects from early method development around cancer pathways or targets and more seamlessly move projects between HTS, Medicinal Chemistry and the BIOC. TAG helps KUCC members navigate the drug discovery, delivery and development process more efficiently.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA168524-07
Application #
9528485
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
7
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Kansas
Department
Type
DUNS #
016060860
City
Kansas City
State
KS
Country
United States
Zip Code
66160
Del Castillo, Erika; Meier, Richard; Chung, Mei et al. (2018) The Microbiomes of Pancreatic and Duodenum Tissue Overlap and are Highly Subject Specific but Differ between Pancreatic Cancer and Non-Cancer Subjects. Cancer Epidemiol Biomarkers Prev :
Cupertino, Ana Paula; Cartujano-Barrera, Francisco; Perales, Jaime et al. (2018) ""Vive Sin Tabaco… ¡Decídete!"" Feasibility and Acceptability of an e-Health Smoking Cessation Informed Decision-Making Tool Integrated in Primary Healthcare in Mexico. Telemed J E Health :
Neums, Lisa; Suenaga, Seiji; Beyerlein, Peter et al. (2018) VaDiR: an integrated approach to Variant Detection in RNA. Gigascience 7:
Preet, Ranjan; Dixon, Dan A (2018) Mutant KRAS Exosomes Influence the Metabolic State of the Colon Microenvironment. Cell Mol Gastroenterol Hepatol 5:647-648
Tomilin, Viktor; Reif, Gail A; Zaika, Oleg et al. (2018) Deficient transient receptor potential vanilloid type 4 function contributes to compromised [Ca2+]i homeostasis in human autosomal-dominant polycystic kidney disease cells. FASEB J 32:4612-4623
Raman, Archana; Parnell, Stephen C; Zhang, Yan et al. (2018) Periostin overexpression in collecting ducts accelerates renal cyst growth and fibrosis in polycystic kidney disease. Am J Physiol Renal Physiol :
Kumar, Dhruv; New, Jacob; Vishwakarma, Vikalp et al. (2018) Cancer-Associated Fibroblasts Drive Glycolysis in a Targetable Signaling Loop Implicated in Head and Neck Squamous Cell Carcinoma Progression. Cancer Res 78:3769-3782
Vishwakarma, Vikalp; New, Jacob; Kumar, Dhruv et al. (2018) Potent Antitumor Effects of a Combination of Three Nutraceutical Compounds. Sci Rep 8:12163
Sharma, Priyanka; López-Tarruella, Sara; García-Saenz, José Angel et al. (2018) Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res 24:5820-5829
Snyder, Vusala; Reed-Newman, Tamika C; Arnold, Levi et al. (2018) Cancer Stem Cell Metabolism and Potential Therapeutic Targets. Front Oncol 8:203

Showing the most recent 10 out of 177 publications